Table: Taisho Pharmaceutical HD -Q1 group results
Aug 2 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2017 Jun 30, 2016 Mar 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 68.53 69.43 279.00
(-1.3 pct) (+0.3 pct) (-0.3 pct)
Operating 6.94 9.11 28.50
(-23.8 pct) (+74.0 pct) (-10.8 pct)
Recurring 8.80 10.42 34.50
(-15.6 pct) (+39.1 pct) (-9.3 pct)
Net 5.53 6.95 24.00
(-20.3 pct) (+48.2 pct) (-16.6 pct)
EPS 69.27 yen 86.92 yen 300.38 yen
EPS Diluted 69.21 yen 86.86 yen
Ann Div 110.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10